Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Roll-over Study of Tafinlar (dabrafenib) and/or Mekinist (trametinib) in Pediatric Patients
jRCT2031220699Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of dabrafenib + trametinib and trametinib in diffuse astrocytoma, anaplastic astrocytoma (AA) and astrocytoma, sponsored by Novartis. Started Jan 2023; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
diffuse astrocytomaanaplastic astrocytoma (AA)astrocytoma
Beyond the preview
Go deeper on jRCT2031220699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220699.